UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mediterranean diet in predementia and dementia syndromes

Current Alzheimer research, 2011-08, Vol.8 (5), p.520-542

2011

Volltextzugriff (PDF)

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid

Current Alzheimer research, 2010-02, Vol.7 (1), p.40-55

2010

Volltextzugriff (PDF)

Metabolic syndrome, mild cognitive impairment, and dementia

Current Alzheimer research, 2011-08, Vol.8 (5), p.492-509

2011

Volltextzugriff (PDF)

CHF5074, a novel γ‐secretase modulator, attenuates brain β‐amyloid pathology and learning deficit in a mouse model of Alzheimer's disease

British journal of pharmacology, 2009-03, Vol.156 (6), p.982-993

2009

Volltextzugriff (PDF)

CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid

Neuroscience, 2015-08, Vol.302, p.112-120

2015

Volltextzugriff (PDF)

Effects of Topical Application of CHF6467, a Mutated Form of Human Nerve Growth Factor, on Skin Wound Healing in Diabetic Mice

The Journal of pharmacology and experimental therapeutics, 2020-11, Vol.375 (2), p.317-331

2020

Volltextzugriff (PDF)

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation

Current medicinal chemistry, 2011-12, Vol.18 (35), p.5430-5447

2011

Volltextzugriff (PDF)

Design of non-conventional biaxial tensile-shear tests for the structural characterization and ductile damage assessment of ductile engineering materials

IOP conference series. Materials Science and Engineering, 2021-02, Vol.1038 (1), p.12068

2021

Volltextzugriff (PDF)

CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice

Neuroscience, 2014-04, Vol.266, p.13-22

2014

Volltextzugriff (PDF)

Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia

Pharmacological research, 2014-03, Vol.81, p.83-90

2014

Volltextzugriff (PDF)

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's Disease

CNS drugs, 2001, Vol.15 (5), p.375-390

IMBIMBO, Bruno Pietro

2001

Volltextzugriff (PDF)

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

The journal of clinical endocrinology and metabolism, 1994-03, Vol.78 (3), p.693-698

1994

Volltextzugriff (PDF)

Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study

Translational psychiatry, 2022-07, Vol.12 (1), p.301-301, Article 301

2022

Volltextzugriff (PDF)

Colonic mass movements in idiopathic chronic constipation

Gut, 1988-09, Vol.29 (9), p.1173-1179

1988

Volltextzugriff (PDF)

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease

Neurology, 1999-03, Vol.52 (4), p.700-700

1999

Volltextzugriff (PDF)

Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects

The journal of clinical endocrinology and metabolism, 1994-11, Vol.79 (5), p.1440-1443

1994

Volltextzugriff (PDF)

Cardiac autonomic dysfunction in patients with Alzheimer disease : Possible pathogenetic mechanisms

Alzheimer disease and associated disorders, 1998-12, Vol.12 (4), p.356-361

1998

Volltextzugriff (PDF)

Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects

Journal of clinical pharmacology, 2003-08, Vol.43 (8), p.901-911

2003

Volltextzugriff (PDF)

Metabolic modulation of the growth hormone-releasing activity of hexarelin in man

Metabolism, clinical and experimental, 1995, Vol.44 (1), p.134-138

1995

Volltextzugriff (PDF)

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty

The journal of clinical endocrinology and metabolism, 1995-04, Vol.80 (4), p.1090-1094

1995

Volltextzugriff (PDF)

Growth hormone-releasing activity of hexarelin in humans : a dose-response study

European journal of clinical pharmacology, 1994-06, Vol.46 (5), p.421-425

1994

Volltextzugriff (PDF)

Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation

Digestive diseases and sciences, 1993-06, Vol.38 (6), p.1040-1045

1993

Volltextzugriff (PDF)

A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease

Dementia and geriatric cognitive disorders, 2000-01, Vol.11 (1), p.17-24

2000

Volltextzugriff (PDF)

Modulation of growth hormone-releasing activity of hexarelin in man

Neuroendocrinology, 1995-01, Vol.61 (1), p.51-56

1995

Volltextzugriff (PDF)

1 – 25 von 227

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(151)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mediterranean diet in predementia and dementia syndromes

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid

Metabolic syndrome, mild cognitive impairment, and dementia

CHF5074, a novel γ‐secretase modulator, attenuates brain β‐amyloid pathology and learning deficit in a mouse model of Alzheimer's disease

CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid

Effects of Topical Application of CHF6467, a Mutated Form of Human Nerve Growth Factor, on Skin Wound Healing in Diabetic Mice

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation

Design of non-conventional biaxial tensile-shear tests for the structural characterization and ductile damage assessment of ductile engineering materials

CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice

Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's Disease

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study

Colonic mass movements in idiopathic chronic constipation

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease

Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects

Cardiac autonomic dysfunction in patients with Alzheimer disease : Possible pathogenetic mechanisms

Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects

Metabolic modulation of the growth hormone-releasing activity of hexarelin in man

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during puberty

Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus: The Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND) Randomized Clinical Trial

Growth hormone-releasing activity of hexarelin in humans : a dose-response study

Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation

A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease

Modulation of growth hormone-releasing activity of hexarelin in man

Suchergebnisse filtern